{"protocolSection": {"identificationModule": {"nctId": "NCT01641081", "orgStudyIdInfo": {"id": "LAC-MD-21"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma", "officialTitle": "Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma."}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-06"}, "primaryCompletionDateStruct": {"date": "2013-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-07-12", "studyFirstSubmitQcDate": "2012-07-12", "studyFirstPostDateStruct": {"date": "2012-07-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-10-27", "resultsFirstSubmitQcDate": "2016-10-27", "resultsFirstPostDateStruct": {"date": "2016-12-22", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2013-02-13", "dispFirstSubmitQcDate": "2013-02-13", "dispFirstPostDateStruct": {"date": "2013-02-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-16", "lastUpdatePostDateStruct": {"date": "2017-02-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.\n\nThis study will include a screening visit followed by a 4 month treatment period."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 174, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Experimental 1", "type": "EXPERIMENTAL", "description": "Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose", "interventionNames": ["Drug: Formoterol Fumarate in the Pressair DPI, Low Dose"]}, {"label": "Experimental 2", "type": "EXPERIMENTAL", "description": "Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose", "interventionNames": ["Drug: Formoterol Fumarate in the Pressair DPI, High Dose"]}, {"label": "Active Comparator 1", "type": "ACTIVE_COMPARATOR", "description": "Foradil Aerolizer, Low Dose", "interventionNames": ["Drug: Foradil Aerolizer, Low Dose"]}, {"label": "Active Comparator 2", "type": "ACTIVE_COMPARATOR", "description": "Foradil Aerolizer, High Dose", "interventionNames": ["Drug: Foradil Aerolizer, High Dose"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Dose matched placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Formoterol Fumarate in the Pressair DPI, Low Dose", "description": "Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days", "armGroupLabels": ["Experimental 1"]}, {"type": "DRUG", "name": "Formoterol Fumarate in the Pressair DPI, High Dose", "description": "Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days", "armGroupLabels": ["Experimental 2"]}, {"type": "DRUG", "name": "Foradil Aerolizer, Low Dose", "description": "Foradil Aerolizer 12 micrograms, twice a day for 14 days", "armGroupLabels": ["Active Comparator 1"], "otherNames": ["Formoterol"]}, {"type": "DRUG", "name": "Foradil Aerolizer, High Dose", "description": "Foradil Aerolizer 24 micrograms, twice per day for 14 days", "armGroupLabels": ["Active Comparator 2"], "otherNames": ["Formoterol"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo in the Pressair for 14 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)", "description": "AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (\u00b15) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (\u00b115 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals", "timeFrame": "Baseline and up to 6 hrs post-dose (\u00b115 min) on Day 14 of treatment"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)", "description": "AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (\u00b15) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (\u00b115 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals", "timeFrame": "Baseline and up to 6 hrs post-dose (\u00b115 min) on Day 1 of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusions:\n\n* Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as defined in the GINA Guidelines) which is unlikely to exacerbate during the study (e.g., due to seasonal allergen exposure).\n* Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at least 30 days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.\n* Qualifying spirometry at Visit 1 demonstrates highest FEV1 is \u2264 85% and \u2265 60% of predicted for age, height, and gender using NHANES III (NHANES 2010) when bronchodilator medications have been withheld the appropriate length of time per the List of Concomitant Medications (Appendix III)\n* Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after the administration of 360 \u00b5g of albuterol.\n* Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the qualifying FEV1 at Visit 1\n\nExclusions:\n\n* Patients with any clinically significant respiratory conditions other than mild to moderate asthma, such as COPD, active tuberculosis, or history of interstitial lung disease\n* Patients with a severe asthma exacerbation requiring hospitalization in the previous 12 months\n* Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at least 6 hours prior to visit", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Esther Garcia, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Forest Investigative Site 909", "city": "Phoenix", "state": "Arizona", "zip": "85006", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Forest Investigative Site 2066", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Forest Investigative Site 1624", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Forest Investigative Site 1995", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Forest Investigative Site 1347", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Forest Investigative Site 1996", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Forest Investigative Site 1137", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Forest Investigative Site 1998", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Forest Investigative Site 2047", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Forest Investigative Site 1536", "city": "Louisville", "state": "Kentucky", "zip": "40215", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Forest Investigative Site 1333", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Forest Investigative Site 1431", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Forest Investigative Site 2041", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Forest Investigative Site 1599", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Forest Investigative Site 1609", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Forest Investigative Site 1999", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Forest Investigative Site 1153", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Forest Investigative Site 1134", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Forest Investigative Site 1806", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Forest Investigative Site 1176", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Forest Investigative Site 2043", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Forest Investigative Site 1580", "city": "Portland", "state": "Oregon", "zip": "97202", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Forest Investigative Site 2025", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Forest Investigative Site 1155", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Forest Investigative Site 1332", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Forest Investigative Site 1370", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Forest Investigative Site 1699", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Forest Investigative Site 2011", "city": "Seattle", "state": "Washington", "zip": "98115", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Forest Investigative Site 1997", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CSR Synopsis", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4059&filename=LAC-MD-21_CSRredacted.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 408 patients were screened; there were 234 screen failures, primarily (225/234) because inclusion/exclusion criteria were not met", "recruitmentDetails": "The study was conducted in 29 study centers in the United States\n\nFirst patient visit was in June 2012 and last patient visit was in February 2013", "groups": [{"id": "FG000", "title": "Sequence 1", "description": "24 \u03bcg Foradil Aerolizer; 12 \u03bcg Foradil Aerolizer; Placebo Pressair; Formoterol 12 \u03bcg Pressair; Formoterol 6 \u03bcg Pressair"}, {"id": "FG001", "title": "Sequence 2", "description": "12 \u03bcg Foradil Aerolizer; Formoterol 12 \u03bcg Pressair; 24 \u03bcg Foradil Aerolizer; Formoterol 6 \u03bcg Pressair; Placebo Pressair"}, {"id": "FG002", "title": "Sequence 3", "description": "Formoterol 12 \u03bcg Pressair; Formoterol 6 \u03bcg Pressair; 12 \u03bcg Foradil Aerolizer; Placebo Pressair; 24 \u03bcg Foradil Aerolizer"}, {"id": "FG003", "title": "Sequence 4", "description": "Formoterol 6 \u03bcg Pressair; Placebo Pressair; Formoterol 12 \u03bcg Pressair; 24 \u03bcg Foradil Aerolizer; 12 \u03bcg Foradil Aerolizer"}, {"id": "FG004", "title": "Sequence 5", "description": "Placebo Pressair; 24 \u03bcg Foradil Aerolizer; Formoterol 6 \u03bcg Pressair; 12 \u03bcg Foradil Aerolizer; Formoterol 12 \u03bcg Pressair"}, {"id": "FG005", "title": "Sequence 6", "description": "Formoterol 6 \u03bcg Pressair; Formoterol 12 \u03bcg Pressair; Placebo Pressair; 12 \u03bcg Foradil Aerolizer; 24 \u03bcg Foradil Aerolizer"}, {"id": "FG006", "title": "Sequence 7", "description": "Placebo Pressair; Formoterol 6 \u03bcg Pressair; 24 \u03bcg Foradil Aerolizer; Formoterol 12 \u03bcg Pressair; 12 \u03bcg Foradil Aerolizer"}, {"id": "FG007", "title": "Sequence 8", "description": "24 \u03bcg Foradil Aerolizer; Placebo Pressair; 12 \u03bcg Foradil Aerolizer; Formoterol 6 \u03bcg Pressair; Formoterol 12 \u03bcg Pressair"}, {"id": "FG008", "title": "Sequence 9", "description": "12 \u03bcg Foradil Aerolizer; 24 \u03bcg Foradil Aerolizer; Formoterol 12 \u03bcg Pressair; Placebo Pressair; Formoterol 6 \u03bcg Pressair"}, {"id": "FG009", "title": "Sequence 10", "description": "Formoterol 12 \u03bcg Pressair; 12 \u03bcg Foradil Aerolizer; Formoterol 6 \u03bcg Pressair; 24 \u03bcg Foradil Aerolizer; Placebo Pressair"}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "17"}, {"groupId": "FG005", "numSubjects": "19"}, {"groupId": "FG006", "numSubjects": "19"}, {"groupId": "FG007", "numSubjects": "17"}, {"groupId": "FG008", "numSubjects": "15"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "19"}, {"groupId": "FG006", "numSubjects": "18"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "15"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "3"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Sponsor request (potential unblinding)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "1"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "2"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "22"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "19"}, {"groupId": "FG006", "numSubjects": "18"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "15"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "21"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "15"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "21"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "15"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "21"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "14"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "21"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "14"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "20"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "14"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}, {"title": "Period 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "20"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "14"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "20"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "18"}, {"groupId": "FG006", "numSubjects": "16"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "14"}, {"groupId": "FG009", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Study Population", "description": "All patients participating in the crossover study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "174"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.4", "spread": "13.2"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "91"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "83"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)", "description": "AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (\u00b15) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (\u00b115 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals", "populationDescription": "Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and up to 6 hrs post-dose (\u00b115 min) on Day 14 of treatment", "groups": [{"id": "OG000", "title": "Foradil 24 \u03bcg", "description": "Administered via Aerolizer"}, {"id": "OG001", "title": "Foradil 12 \u03bcg", "description": "Administered via Aerolizer"}, {"id": "OG002", "title": "Formoterol 12 \u03bcg", "description": "Administered via Pressair"}, {"id": "OG003", "title": "Formoterol 6 \u03bcg", "description": "Administered via Pressair"}, {"id": "OG004", "title": "Placebo", "description": "Administered via Pressair"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "155"}, {"groupId": "OG003", "value": "159"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3196", "spread": "0.0382"}, {"groupId": "OG001", "value": "0.3076", "spread": "0.0382"}, {"groupId": "OG002", "value": "0.2795", "spread": "0.0382"}, {"groupId": "OG003", "value": "0.2726", "spread": "0.0381"}, {"groupId": "OG004", "value": "0.0552", "spread": "0.0382"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate", "paramType": "Least squares mean difference", "paramValue": "0.2644", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2353", "ciUpperLimit": "0.2934", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0148"}, {"groupIds": ["OG001", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate", "paramType": "Least squares mean difference", "paramValue": "0.2524", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2218", "ciUpperLimit": "0.2830", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0156"}, {"groupIds": ["OG002", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate", "paramType": "Least squares mean difference", "paramValue": "0.2242", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.1941", "ciUpperLimit": "0.2544", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0153"}, {"groupIds": ["OG003", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Treatment and period as fixed effects, and baseline FEV1 values at each period as a covariate", "paramType": "Least squares mean difference", "paramValue": "0.2174", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.1887", "ciUpperLimit": "0.2461", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0146"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)", "description": "AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (\u00b15) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (\u00b115 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals", "populationDescription": "Intent to treat (ITT) Population defined as all patients in the Safety Population who had a baseline and at least 1 post-baseline FEV1 assessment", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and up to 6 hrs post-dose (\u00b115 min) on Day 1 of treatment", "groups": [{"id": "OG000", "title": "Foradil 24 \u03bcg", "description": "Administered via Aerolizer"}, {"id": "OG001", "title": "Foradil 12 \u03bcg", "description": "Administered via Aerolizer"}, {"id": "OG002", "title": "Formoterol 12 \u03bcg", "description": "Administered via Pressair"}, {"id": "OG003", "title": "Formoterol 6 \u03bcg", "description": "Administered via Pressair"}, {"id": "OG004", "title": "Placebo", "description": "Administered via Pressair"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "155"}, {"groupId": "OG002", "value": "159"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3544", "spread": "0.0196"}, {"groupId": "OG001", "value": "0.3068", "spread": "0.0198"}, {"groupId": "OG002", "value": "0.2712", "spread": "0.0197"}, {"groupId": "OG003", "value": "0.2204", "spread": "0.0197"}, {"groupId": "OG004", "value": "0.0306", "spread": "0.0198"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 14\u00b11 of the final treatment period (Period 5)", "description": "The Safety Population consisted of all patients screened, randomized to a treatment sequence, and who took at least one dose of double-blind investigational product The total number of patients in the Safety Population was 174; due to study drop-out and the crossover study design, not all patients received all treatments", "eventGroups": [{"id": "EG000", "title": "Foradil 24 \u03bcg", "description": "Administered via Aerolizer", "seriousNumAffected": 0, "seriousNumAtRisk": 167, "otherNumAffected": 10, "otherNumAtRisk": 167}, {"id": "EG001", "title": "Foradil 12 \u03bcg", "description": "Administered via Aerolizer", "seriousNumAffected": 2, "seriousNumAtRisk": 163, "otherNumAffected": 2, "otherNumAtRisk": 163}, {"id": "EG002", "title": "Formoterol 12 \u03bcg", "description": "Administered via Pressair", "seriousNumAffected": 0, "seriousNumAtRisk": 164, "otherNumAffected": 2, "otherNumAtRisk": 164}, {"id": "EG003", "title": "Formoterol 6 \u03bcg", "description": "Administered via Pressair", "seriousNumAffected": 0, "seriousNumAtRisk": 166, "otherNumAffected": 1, "otherNumAtRisk": 166}, {"id": "EG004", "title": "Placebo", "description": "Administered via Pressair", "seriousNumAffected": 0, "seriousNumAtRisk": 165, "otherNumAffected": 0, "otherNumAtRisk": 165}], "seriousEvents": [{"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA v 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 164}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 165}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 164}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 165}]}], "otherEvents": [{"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 167}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 163}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 164}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 165}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Publication of the results by the PI will be subject to mutual agreement between the PI and sponsor."}, "pointOfContact": {"title": "Study Director", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Channel", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}